Thursday, March 28, 2024
Home Tags Nasdaq:AMRN

Tag: Nasdaq:AMRN

Amarin to Present at Two Investor Conferences in June 2021

0
DUBLIN, Ireland and BRIDGEWATER, N.J., May 18, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero,...

REDUCE-IT® Heart Failure Analyses by VASCEPA® (Icosapent Ethyl)-Driven Serum Eicosapentaenoic Acid...

0
Post hoc analyses by estimated on-treatment serum EPA levels in the VASCEPA group suggest potentially reduced incidence of new heart failure and new...

Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines...

0
VAZKEPA (icosapent ethyl) is the first and only authorized treatment for its cardiovascular risk reduction indication1,2,3 VAZKEPA authorization for Great Britain follows...

VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in...

0
Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA® (icosapent ethyl) on top of statin therapy Effect...

Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent...

0
Reimbursement dossiers for first 10 countries to be filed in coming months 150 people hired and on-track to be deployed by mid-Q2...

Amarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular...

0
Marks first and only EC-approved treatment to reduce cardiovascular risk in high-risk, statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and other...

Press Realease

Business News

Cricket

Weather News

Lifestyle

World News

UK / USA News

Local News